Gynecologic Oncology Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Gynecologic Oncology Group sits in the top decile of US sponsors by registered trial count (#189 of 15,742 sponsors by registered trial count).
Gynecologic Oncology Group: 154 sponsored US clinical trials, 1 recruiting.
Gynecologic Oncology Group sponsors 154 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 115 completed. 27 of these trials are in Phase 3-4 (later-stage) and 107 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cervical Cancer, with 6 trials.
Top-decile sponsor footprint
Gynecologic Oncology Group ranks in the top decile of sponsors by registered trial count (#189 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
115 of 151 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
154 total, page 3 of 4
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00005840
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00005830
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00006011
Chemotherapy in Treating Patients With Sarcoma of the Uterus
NCT00005643
Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer
NCT00005861
Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
NCT00005046
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
NCT00005026
Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer
NCT00005837
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
NCT00005836
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00005029
Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
NCT00003325
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
NCT00003377
Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT00071929
Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer
NCT00003379
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
NCT00004221
Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia
NCT00003688
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003967
Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer
NCT00003946
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT00003386
Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
NCT00003945
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia
NCT00003702
Quality of Life in Survivors of Gynecologic Cancer
NCT00003795
Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer
NCT00003794
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003385
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum
NCT00003523
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00003691
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
NCT00003624
Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer
NCT00003179
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
NCT00003644
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer
NCT00003384
Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
NCT00003316
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer
NCT00003378
Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus
NCT00003156
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
NCT00004037
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00003380
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
NCT00003382
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
NCT00003322
Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus
NCT00003128
Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix
NCT00003078
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer
NCT00002813
Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus
NCT00002993
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
NCT00003054
Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
NCT00002976
Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer
NCT00002536
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
NCT00002819
Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus
NCT00002706
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00002717
Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002568
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
NCT00002562
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus
NCT00002546
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 86 |
| Phase 3 | 27 |
Therapeutic Areas
What is open in the Gynecologic Oncology Group pipeline
1 recruiting of 154 indexed (1% open); 115 completed (75%).
Phase mix: 27 late (III/IV) vs 107 early (I/II) (early-phase heavy).
Top condition: Cervical Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Gynecologic Oncology Group: open-pipeline peers nationwide
Peers matched on 154 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Gynecologic Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 154 trials (± recruiting share)
- Sanofi Pasteur, a Sanofi Company · 153 trials · 2% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Galderma R&D · 158 trials · 4% recruiting
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
Sponsors near 1% open enrollment (± trial volume)
- Mylan Pharmaceuticals · 1% recruiting · 146 trials
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- Shire · 0% recruiting · 245 trials
- Abbott Nutrition · 1% recruiting · 89 trials
Related
What to do with this Gynecologic Oncology Group page
154 registered trials is a research-attention snapshot, not an endorsement of Gynecologic Oncology Group or any single study.
- 1 of Gynecologic Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cervical Cancer is the condition Gynecologic Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cervical Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Gynecologic Oncology Group pipeline card: 154 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.